A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute …
Abstract Objective Arachidonate 5-lipoxygenase (5-LO) is a key enzyme in the synthesis of
leukotrienes. VIA-2291 is a potent 5-LO inhibitor, which has been shown to reduce hsCRP
and noncalcified coronary plaque volume following an acute coronary syndrome (ACS). We
aim to evaluate the effect of VIA-2291 on vascular inflammation compared to placebo using
FDG-PET. Methods A Phase II, randomized, double-blind, parallel-group study was
conducted in 52 patients with recent ACS assigned 1: 1 to either 100 mg VIA-2291 or …
leukotrienes. VIA-2291 is a potent 5-LO inhibitor, which has been shown to reduce hsCRP
and noncalcified coronary plaque volume following an acute coronary syndrome (ACS). We
aim to evaluate the effect of VIA-2291 on vascular inflammation compared to placebo using
FDG-PET. Methods A Phase II, randomized, double-blind, parallel-group study was
conducted in 52 patients with recent ACS assigned 1: 1 to either 100 mg VIA-2291 or …